GNVC Stock UPDATES Genvec Inc (GNVC) 1.75 10/21/2014 23:51:5

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Genvec Inc (GNVC) 1.75 $GNVC

Zola P. Horovitz To Retire From GenVec Board
PR Newswire - Mon Oct 20, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced the retirement of Zola P. Horovitz, Ph.D., from its board of directors effective on October 24, 2014. Dr. Horovitz joined the GenVec board in August 2003, and served as its chairman from June 2006 to November 2013. During his tenure, he also served on the Nominating and Corporate Governance and Audit Committees of the board.
GNVC: 1.75 (+0.03)

GenVec Reports Second Quarter 2014 Financial Results
PR Newswire - Tue Aug 12, 6:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year. For the six-month period ended June 30, 2014, the company reported a net loss of $2.6 million or $0.17 per share on revenues of $2.3 million as compared to a net loss of $6.2 million or $0.48 per share on revenues of $2.0 million in the same period in the prior year. GenVec ended the second quarter of 2014 with $14.6 million in cash, cash equivalents, and liquid investments.
GNVC: 1.75 (+0.03)

GenVec Reports Fourth Quarter and 2013 Year-End Financial Results
PR Newswire - Fri Mar 28, 6:40AM CDT
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012. GenVec ended the year with $6.1 million in cash, cash equivalents, and short-term investments.
GNVC: 1.75 (+0.03)

Why GenVec (GNVC) Stock Is Up In Aftermarket Trading
at The Street - Thu Mar 27, 4:36PM CDT
Shares of GenVec (GNVC) were up 12.83% to $2.99 in aftermarket trading Thursday.
GNVC: 1.75 (+0.03)

GenVec To Release Fourth Quarter And Year-End 2013 Financial Results And Conduct A Conference Call On March 28, 2014
PR Newswire - Fri Mar 21, 7:00AM CDT
GenVec, Inc. (NASDAQ: GNVC) will report financial results for the fourth quarter and year ended December 31, 2013 on Friday, March 28, 2014, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call at 10:00 a.m. EDT to discuss the company's fourth quarter and 2013 financial results as well as recent highlights and the 2014 business outlook.
GNVC: 1.75 (+0.03)

GenVec Announces $9 Million Registered Direct Offering
PR Newswire - Thu Mar 13, 7:51AM CDT
GenVec, Inc. (NASDAQ: GNVC) ("GenVec" today announced it has agreed to sell approximately $9 million of shares of its common stock to selected institutional investors in a registered direct offering at a price of $3.15 per share. In the offering, GenVec will issue approximately 2,870,000 shares of its common stock. The closing of the offering is expected to take place on or about March 18, 2014, subject to the satisfaction of customary closing conditions.
GNVC: 1.75 (+0.03)

GenVec to Present at 26th Annual ROTH Conference
PR Newswire - Mon Mar 03, 7:00AM CST
GenVec, Inc. (NASDAQ:GNVC) announced today that the Company will participate in the 26th Annual ROTH Conference being held March 9-12, 2014 in Dana Point, California. Douglas Swirsky, President and CEO of GenVec, will present a company overview on Monday, March 10, 2014 at 3:00 pm Pacific Daylight Time.
GNVC: 1.75 (+0.03)

GenVec Achieves Third Milestone In Hearing And Balance Collaboration
PR Newswire - Thu Feb 13, 5:00AM CST
GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders. In January 2014, Novartis filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for the clinical development of CGF166, the lead product candidate under the collaboration. The IND was deemed effective on February 7, 2014 and this triggered a $2 million milestone payment to GenVec under the terms of the collaboration.
GNVC: 1.75 (+0.03), NVS: 88.61 (+0.71)

AutoGrid and Big Data Energy Services Announce Strategic Partnership to Deliver Demand Response (DR) Capabilities to Texas' Largest Electric Providers
Marketwire - Thu Dec 19, 6:32AM CST
AutoGrid Systems, a leader in innovative solutions for the electricity and energy industry, is proud to announce a strategic partnership with Big Data Energy Services (BDES), a cloud-based service provider and consulting firm, to deliver services and technology that will allow electricity providers to reduce the cost of power for their customers while mitigating the risk of sharply higher prices in tight energy markets.
SMSI: 0.84 (+0.01), GNVC: 1.75 (+0.03), LIVE: 3.10 (+0.47), SMRT: 12.60 (+0.06)

PowerCloud Systems and Common Sense Media Join Forces to Help Kids and Families Make Smart Choices Online
PR Newswire - Wed Dec 18, 7:00AM CST
PowerCloud Systems, a pioneer in cloud networking for the connected home, and Common Sense Media, the largest non-partisan, not-for-profit organization dedicated to helping kids thrive in a world filled with media and technology, today announced a partnership dedicated to facilitating easy access to age-appropriate Internet content in the home. PowerCloud Systems is the creator of Skydog(TM), the revolutionary home networking solution used by thousands of families to manage their connected lives by providing unprecedented visibility into, and management over, their home networks. This partnership will give Skydog users easy access to Common Sense Media's independent, age-based ratings and reviews of online media, based on developmental criteria from some of the nation's leading authorities, and provide a technical solution for the family to manage access to this media.
GNVC: 1.75 (+0.03)

Nasdaq stocks posting largest volume increases
AP - Fri Sep 06, 5:07PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
TOPS: 1.81 (+0.16), GNVC: 1.75 (+0.03), ACST: 0.56 (unch), SHIP: 1.53 (+0.05), CONN: 31.07 (+1.31), LTXC: 9.35 (+0.45), UNTY: 8.95 (-0.14), VIDE: 2.92 (+0.02)

Five Star Equities Issues New Research Reports on GNVC, RMTI, SAI and SNDK
ACCESSWIRE - Thu Sep 05, 7:40AM CDT
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
GNVC: 1.75 (+0.03)

GenVec Board Restructures Operations and Withdraws Plan of Dissolution
PR Newswire - Wed Sep 04, 7:30AM CDT
GenVec, Inc. (NASDAQ: GNVC) today announced that its Board of Directors withdrew the Plan of Complete Liquidation and Dissolution for the Company previously adopted on May 24, 2013. The Company also announced that it will pursue a strategy focused on maximizing the value of its technology and assets, including its collaboration with Novartis to develop novel treatments for hearing loss.
GNVC: 1.75 (+0.03), NVS: 88.61 (+0.71)

Traders Get Bullish on Shares of GenVec, Shares Up 17.1% (GNVC)
Comtex SmarTrend(R) - Tue Jun 25, 11:36AM CDT
GenVec (NASDAQ:GNVC) is one of today's best performing penny stocks, up 17.1% to $0.41 on 1.1x average daily volume. GenVec has traded 301,000 shares thus far today, vs. average volume of 269,000 shares per day. The stock has outperformed the Dow (17.1% to the Dow's 0.7%) and outperformed the S&P 500 (17.1% to the S&P's 0.9%) during today's trading.
GNVC: 1.75 (+0.03)

GenVec Q4 Net Loss Deepens
Eric Volkman, The Motley Fool - Motley Fool - Fri Mar 22, 4:51PM CDT
GenVec results for the company’s Q4 and fiscal 2012 have been released. For the quarter, revenue was $1.5 million, less than half the $3.4 million of the same period the previous year. Attributable net loss deepened over that time span,...
GNVC: 1.75 (+0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 0

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 23

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 258

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 102

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 63

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 41

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 106

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Into Guess?, Inc.: Are Fiduciary Duties at Risk?

Updated Category News Views 121

Introduction to the Investigation Recently, a significant issue has arisen concerning Guess?, Inc. (NYSE: GES) and its handling of a pending merger with Authentic Brands Group LLC. This acquisition deal, valued at $16.75 per share, has prompted a legal investigation to determine whether the company's board of directors and top executives may have breached their fiduciary...

Continue Reading
Count Down to Class Action: Important News for GO Investors

Updated Category News Views 281

Important Deadline for Grocery Outlet Holding Corp. Investors As the deadline for the class action lawsuit approaches for Grocery Outlet Holding Corp. (NASDAQ: GO), investors are urged to pay close attention. The law firm Kessler Topaz Meltzer & Check, LLP has announced that investors who purchased or acquired Grocery Outlet securities from November 7, 2023, to May 7,...

Continue Reading
Discover KLIMB Jr.: The Latest in Pet Training Innovation

Updated Category News Views 239

Introducing the KLIMB Jr. by Blue-9 Pet Products Blue-9 Pet Products has made a remarkable stride in pet care with the introduction of the KLIMB Jr., a compact and versatile training platform for dogs and cats. This innovative product serves as a perfect tool for pet owners aiming to enhance their pets’ training and daily enrichment activities. A Tailored Solution for...

Continue Reading
Elsevier, Lancet Awards Highlight Community Health Impact

Updated Category News Views 62

Pioneering Health Awards Make Waves Amidst our swirling universe of breakthroughs and challenges, three research teams just snagged the spotlight. Recognized by the Elsevier Foundation and The Lancet in their first-ever Evidence to Impact Awards. These folks aren't just scribbling in labs—they're rolling up their sleeves and getting those much-needed health solutions...

Continue Reading
k-ID's Kai SDK: Age-Adaptive Design Revolution

Updated Category News Views 139

New Horizons for Developers Today, if you're building an app, you're just as likely to be wrangling with legal regulations as you are writing code. That's where k-ID’s new SDK, Kai, comes into play—it's not just another tool in the shed, it’s the whole toolbox for dealing with age-specific app requirements everywhere. The Changing App Landscape Why does this matter?...

Continue Reading